Navigation Links
Vermillion Announces Return of Eric Fung, M.D., Ph.D.
Date:10/2/2009

ive immunoassays into a single numerical score. It is indicated for women who meet the following criteria: over age 18, ovarian adnexal mass present for which surgery is planned, and not yet referred to an oncologist. The test utilizes five well-established biomarkers --- Transthyretin (TT or prealbumin), Apolipoprotein A-1 (Apo A-1), Beta2-Microglobulin (Beta2M), Transferrin (Tfr) and Cancer Antigen 125 (CA 125 II) -- and a proprietary algorithm to determine the likelihood of malignancy in women with pelvic mass for whom surgery is planned.

The OVA1 Test is an aid to further assess the likelihood that malignancy is present when the physician's independent clinical and radiological evaluation does not indicate malignancy. The test should not be used without an independent clinical/radiological evaluation and is not intended to be a screening test or to determine whether a patient should proceed to surgery. Incorrect use of the OVA1 Test carries the risk of unnecessary testing, surgery, and/or delayed diagnosis.

Quest Diagnostics, which is a long-time investor in research and development of the OVA1 technology, has exclusive rights to offer the test to the clinical reference laboratory market in the U.S. for three years.

About Vermillion

Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, hematology, cardiology and women's health. Vermillion is based in Fremont, California. Additional information about Vermillion can be found on the Web at http://www.vermillion.com.

    Contact:

    Vermillion:
    Jill Totenberg
    The Totenberg Group
    Tel:  212 994 7363
    '/>"/>
SOURCE Vermillion, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vermillion (Formerly Ciphergen) Announces $20.5 Million Private Placement of Common Stock
2. Vermillion and Collaborators Discover Protein Biomarker Associated with Peripheral Artery Disease
3. Vermillion, Inc. Announces Receipt Of Notice Of Compliance From Nasdaq
4. Vermillion to Webcast Presentation at the Acumen BioFin 9th Annual Healthcare Conference, November 5-7, New York
5. Vermillion and Johns Hopkins Sign Collaborative Research and License Agreements to Develop Molecular Diagnostic Tests
6. Vermillion Receives NASDAQ Notice of Non-Compliance
7. Vermillion and Stanford University Sign Exclusive License Agreement for Novel Biomarker Panel to Assess Peripheral Artery Disease Risk
8. Vermillion Announces Effectiveness of Reverse Stock Split
9. Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones
10. Vermillion Meets Minimum Bid Price and Receives NASDAQ Staff Determination Letter for Minimum Market Capitalization
11. Vermillion Biomarker Panel Potential Aid in the Diagnosis of Peripheral Artery Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... device," Nobel laureate Herbert Kroemer famously observed, referring ... the junctures where layers of different materials meet. ... between layers of metal oxides are becoming increasingly ... spintronics, high-temperature superconductors, ferroelectrics and multiferroics. Realizing the ...
(Date:1/15/2014)... 15, 2014   Niagara Thermal Products is proud ... BioBlower Technologies LLC ("B3") as the critical thermal component ... from the Army Corps of Engineers.  B3 has developed ... biological contaminants and destroys VOCs and other chemical pollutants, ...
(Date:1/15/2014)... and SAN JOSE, California , January ... company developing antibody-drug conjugates for cancer, today announced the appointment ... Directors. Dr Reynolds has over 20 years, development experience gained ... at Seattle Genetics. "I am delighted to welcome ...
(Date:1/15/2014)... 2014 A study has been launched to ... 1 track could help to tackle the problem of obesity. ... (a GP surgery based in Stowmarket) and academics at University ... Telemetry technology, which is inspired by equipment used to ...
Breaking Biology Technology:A deeper look at interfaces 2Niagara Thermal Products LLC Selected as Critical Supplier for Buffalo BioBlower Air Purification Systems 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4
... VIEW, Calif., Nov. 7, 2011 VIVUS, Inc. (NASDAQ: ... and commercialization of novel therapeutic products, today reported its financial ... 30, 2011. Third Quarter ResultsFor the ... loss of $8.6 million, or $0.10 net loss per share, ...
... November 7, 2011 Note: numbers in square ... Boulter is available for interview. Investment fund manager ... today won a court battle with 3M over the multi-national ... The High Court in London found 3M was ...
... HANOVER, N.J., Nov. 7, 2011 Novartis announced today ... with active systemic juvenile idiopathic arthritis (SJIA) were able ... described as steroids) within 28 weeks of commencing treatment ... of the study, which met both primary endpoints, will ...
Cached Biology Technology:VIVUS Reports Third Quarter and First Nine Months 2011 Financial Results 2VIVUS Reports Third Quarter and First Nine Months 2011 Financial Results 3VIVUS Reports Third Quarter and First Nine Months 2011 Financial Results 4VIVUS Reports Third Quarter and First Nine Months 2011 Financial Results 5VIVUS Reports Third Quarter and First Nine Months 2011 Financial Results 6VIVUS Reports Third Quarter and First Nine Months 2011 Financial Results 7VIVUS Reports Third Quarter and First Nine Months 2011 Financial Results 8VIVUS Reports Third Quarter and First Nine Months 2011 Financial Results 93M Forced to Pay for Breach of Obligations Over MRSA - High Court 23M Forced to Pay for Breach of Obligations Over MRSA - High Court 33M Forced to Pay for Breach of Obligations Over MRSA - High Court 4Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis 2Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis 3Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis 4Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis 5Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis 6Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis 7
(Date:4/17/2014)... MANHATTAN, KAN. A Kansas State University engineer ... security and remotely detects improvised explosive devices. The ... , William Dunn, the Steven M. and Kay ... of mechanical and nuclear engineering, and his research ... explosives hidden underground or in car trunks. The ...
(Date:4/17/2014)... Calif. One day about eight years ago, ... California, Riverside, and her father were on a field trip ... upon an orchid they had never seen before. , Unable ... on orchids. The orchid turned out to be an ... Lophiaris silverarum . , "Lophiaris" is the genus name, ...
(Date:4/17/2014)... is available in German . ... the protection money demanded of him, he can expect his ... however, as fear of the consequences is enough to make ... parasitic birds, which lay their eggs in other birds, nests. ... brood parasites take their revenge by destroying the entire nest. ...
Breaking Biology News(10 mins):Patented research remotely detects nitrogen-rich explosives 2Orchid named after UC Riverside researcher 2Orchid named after UC Riverside researcher 3Fear of the cuckoo mafia 2Fear of the cuckoo mafia 3
... 2012 Chiltern International Limited (Chiltern), a global contract ... James Gunter have joined Chiltern, bringing their expertise in ... strengthen our Global Clinical Development services. ... Cedric Burg has been appointed to the position of ...
... pests by using ultrasonic frequencies are available and marketed ... been demonstrated as being effective in repelling insect pests ... of evidence for the efficacy of such devices, they ... bugs are readily available. However, according to a ...
... reprogramming a 7-year-old girl,s own immune cells to attack ... has achieved a complete response in his patient, who ... The innovative experimental therapy used bioengineered T cells, custom-designed ... leukemia cells. After the treatment, the child,s doctors found ...
Cached Biology News:Chiltern Welcomes Cedric Burg And James Gunter 2Engineered immune cells produce complete response in child with an aggressive pediatric leukemia 2Engineered immune cells produce complete response in child with an aggressive pediatric leukemia 3
... cultured in DMEM with 4 mM L-glutamine medium ... In order to keep the antigens in ... The cells are arrayed on a 12-well ... surface specifically treated to enhance cellular attachment and ...
... cultured in DMEM and harvested at the log ... the antigens in their native forms, cells were ... on a 12-well (5 mm) adhesive coated slide, ... cellular attachment and to minimize background staining. ...
... P815 cells were cultured in DMEM and harvested ... order to keep the antigens in their native ... cells are arrayed on a 12-well (5 mm) ... treated to enhance cellular attachment and to minimize ...
...
Biology Products: